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Abstract
Background: Particulate matter has been shown to stimulate the innate immune system and induce acute
inflammation. Therefore, while nanotechnology has the potential to provide therapeutic formulations with
improved efficacy, there are concerns such pharmaceutical preparations could induce unwanted inflammatory
side effects. Accordingly, we aim to examine the utility of using the proteolytic activity signatures of cysteine
proteases, caspase 1 and cathepsin S (CTSS), as biomarkers to assess particulate-induced inflammation.
Methods: Primary peritoneal macrophages and bone marrow-derived macrophages from C57BL/6 mice and ctss−/−
mice were exposed to micro- and nanoparticulates and also the lysosomotropic agent, L-leucyl-L-leucine methyl ester
(LLOME). ELISA and immunoblot analyses were used to measure the IL-1β response in cells, generated by lysosomal
rupture. Affinity-binding probes (ABPs), which irreversibly bind to the active site thiol of cysteine proteases, were then
used to detect active caspase 1 and CTSS following lysosomal rupture. Reporter substrates were also used to quantify
the proteolytic activity of these enzymes, as measured by substrate turnover.
Results: We demonstrate that exposure to silica, alum and polystyrene particulates induces IL-1β release from
macrophages, through lysosomal destabilization. IL-1β secretion positively correlated with an increase in the
proteolytic activity signatures of intracellular caspase 1 and extracellular CTSS, which were detected using ABPs and
reporter substrates. Interestingly IL-1β release was significantly reduced in primary macrophages from ctss−/− mice.
Conclusions: This study supports the emerging significance of CTSS as a regulator of the innate immune response,
highlighting its role in regulating IL-1β release. Crucially, the results demonstrate the utility of intracellular caspase 1
and extracellular CTSS proteolytic activities as surrogate biomarkers of lysosomal rupture and acute inflammation. In the
future, activity-based detection of these enzymes may prove useful for the real-time assessment of particle-induced
inflammation and toxicity assessment during the development of nanotherapeutics.
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Background
Non-biodegradable particulate matter, such as silica and
asbestos, has been shown to stimulate the innate immune
system and cause acute inflammation [1]. Accumulation of
particulates in the airways from chronic exposure leads to
cell injury, silicosis and progressive lung fibrosis, and is as-
sociated with autoimmunity, lung cancer and cardiopulmo-
nary failure [2]. Accordingly, while rapid progress is being
made in the application of nanotechnology in therapeutics,
primarily for medical diagnostics and drug delivery, there
are concerns that such pharmaceutical preparations could
induce the same unwanted inflammatory and toxic side ef-
fects as incidental particulate matter. Therefore, dissecting
the common mechanisms which underlie particle-induced
inflammation warrants further investigation and identifying
biomarkers to monitor the initial stages of this process
may prove useful.
Once in the circulation, particulate matter can be ingested
by resident macrophages inducing a pro-inflammatory
phenotype that if unchecked or prolonged, can inadvert-
ently induce tissue damage and fibrosis [3]. A key early
proinflammatory cytokine released from macrophages is
interleukin 1 beta (IL-1β). Normally under stringent control
in physiological conditions, IL-1β dysregulation has been
shown to underlie a diverse range of diseases including
Alzheimer’s disease, silicosis and rheumatoid arthritis [4, 5].
Post-translational processing of pro-IL-1β into its bio-
logically active form is facilitated by the formation of a
multi-molecular complex termed the inflammasome, which
acts as a platform to drive the autocatalytic processing and
activation of pro-caspase 1, which subsequently cleaves
pro- IL-1β to mature IL-1β, which is then secreted [6, 7].
The assembly of the inflammasome requires activation of a
cytosolic, danger-sensing Nod-like receptor (NLR) in re-
sponse to inflammatory stimuli or cellular stress. The most
extensively studied NLR, NLRP3, is activated in response to
a variety of crystalline and particulate matter, including
silica, alum, monosodium urate crystals, cholesterol
crystals and amyloid fibres [8–12]. As many particulates
trigger lysosomal rupture following phagocytosis by
macrophages, a relationship between lysosomal desta-
bilisation and NLRP3 inflammasome activation has
been established and is thought to be mediated by leak-
age of lysosomal cathepsins [13–15].
The increasing appreciation for the roles of proteases,
such as cathepsins, in pathological conditions has led to
much interest in their prognostic and diagnostic potential
[16]. Thus, while levels of IL-1β can be easily determined
using ELISA or associated technologies, we hypothesized
that the measurement of caspase 1 and cathepsin activities
may constitute alternative, more useful real-time readouts
of lysosomal disruption and particle-induced acute inflam-
mation. Furthermore, using activity-based proteomic de-
tection methods, proteolytic activities may prove more
translatable to in vivo imaging applications, which could
assess the potential toxicity of particulates directly and in
real time [17].
In this current study, we examine the potential of using
caspase 1 and cathepsin S (CTSS) activation as a readout
of lysosomal disruption and acute inflammation. We re-
port that CTSS activity may represent an extracellular
marker of particle-induced inflammation as opposed to
intracellular caspase 1 activation. Furthermore, we dem-
onstrate that that CTSS plays a significant role in IL-1β
secretion from particulate-treated macrophages, highlight-
ing an unappreciated role for CTSS in the innate immune
response.
Results
Particulates induce the release of proinflammatory
mediator IL-1β in both peritoneal and bone marrow
derived macrophages
In our initial experiments we validated that particulate
matter had the ability to induce the release of IL-1β as
previously described [11, 13]. We examined the potential
of different particle compositions to activate IL-1β re-
sponses in macrophages which were primed with toll-like
receptor ligand, LPS to induce the initial expression of
pro- IL-1β. We found that a range of non-biodegradable
particulates including alum microparticles, 3–10 μm in
diameter, and silica and polystyrene nanoparticles (PSNP),
both 100 nm in diameter, induced the release of IL-1β
from both LPS-primed peritoneal and bone marrow de-
rived macrophages (BMDMs), in a dose-dependent man-
ner (Fig. 1a and b respectively). Furthermore, we were
able to mimic the effect of particulates on IL-1β release
through the treatment of macrophages with the lysosomo-
tropic agent, L-leucyl-L-leucine methyl ester (LLOME)
(Fig. 1a(iv) and b(iv)). LLOME acts as a detergent which
accumulates in acidic vesicles, inducing lysosomal rupture
and has been previously employed as a surrogate reagent
to analyse particle-induced inflammation [14]. Interest-
ingly, no measurable release of IL-1β from the cells was
observed upon co-incubation with comparable concentra-
tions of biodegradable 150 nm poly-lactide-co-glycolic
acid (PLGA) nanoparticles (Additional file 1: Figure S1).
To ascertain if the particles were affecting lysosomal
integrity, lysosomes in peritoneal macrophages were
stained with acridine orange and visualised using mi-
croscopy (Fig. 1c). In the untreated cells, acridine or-
ange accumulated in acidic lysosomal compartments
which can be seen as highly concentrated red fluores-
cence in the cytosol, in a punctate pattern. However,
treatment with particulates led to a dramatic reduc-
tion in red fluorescence in the cells, indicative of loss
of lysosomal integrity and lysosomal rupture [18–20].
Staining of lysosomes following treatment of periton-
eal macrophages with LLOME showed a similar effect
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on lysosomal staining (Fig. 1c). Taken together, these
results confirm that non-biodegradable particulates in-
duce the release of IL-1β in macrophage populations
through destabilisation of lysosomal compartments,
and we also establish that LLOME can be employed
to replicate this effect in vitro.
Caspase 1 activity can be visualised upon particle-induced
lysosomal disruption
IL-1β is produced and stored as a precursor (pro-IL-1β)
that must be activated by the cytoplasmic cysteine prote-
ase, caspase 1, prior to secretion. Caspase 1 is produced as
an inactive zymogen and requires proteolytic activation by
the inflammasome. Caspase 1 activity in cell lysates can be
selectively detected using the 7-Amino-4-methylcoumarin
(AMC)-labelled fluorogenic peptidyl reporter substrate, Z-
Tyr-Val-Ala-Asp-AMC. Upon proteolytic cleavage of the
peptidyl sequence by caspase 1, a detectable shift in the
emission spectrum of the fluorophore is produced, which
acts as a readout of caspase 1 activity. Using LLOME as a
model inducer of lysosomal rupture, it was demonstrated
that stimulation of BMDMs led to an increase in cytoplas-
mic caspase 1 activity levels, which was apparent within
0.5 h and increased up to 6 h (Fig. 2a). In addition to using
fluorogenic substrates, proteolytic activity can also be vi-
sualized using ABPs which act as suicide substrates, that
A) i) ii) iii) iv)
B) i) ii) iii) iv)
C) i) ii) iii) iv) v)
Fig. 1 Particulates and LLOME induce perturbations in lysosomal compartments leading to the release of IL-1β. ELISA analysis of IL-1β production
in supernatants harvested from: a Peritoneal macrophages primed for 3 h with LPS (100 ng/mL) and stimulated for 16 h with a concentration range
(10–1000 μg/mL, 22–2200 pg/cell) of i) alum, ii) silica, iii) PSNP, iv) LLOME, b BMDMs primed for 3 h with LPS (100 ng/mL) and stimulated for 16 h with
a concentration range (10–1000 μg/mL, 22–2200 pg/cell) of i) alum, ii) silica, iii) PSNP, iv) LLOME. For all experiments n= 4 +/− standard error. c Confocal
microscopy of acidified lysosomes labelled with acridine orange (3 μM) in peritoneal macrophages which were i) left untreated or treated for 4 h with
ii) 500 μg/mL alum, iii)250 μg/mL silica, iv) 500 μg/mL PSNP, v) 0.5 mM LLOME. Top panel: nuclear dapi stain (blue) + acridine orange (red). Lower panel:
acridine orange only. Images representative of 2 independent experiments., scale bar = 20 μm
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A)
B)
D) i) ii) iii) iv)
E) i) ii) iii) F)
i) ii) iii)
C)
Fig. 2 Caspase 1 is act ivat ed following LLOME and part icl e-induced lysosomal rupture in macrophages. a Caspase 1 act ivity in lysat es from LPS-pr
imed BMDMs, tr eated with LLOME (0.5 mM) for 0.5 h to 6 h. Act ivity was measured using r eporter substrate Z-YVAD-AMC (60 μM), which upon
hydrolysis by caspase 1produces a det ectabl e shift in RFU, n = 4 +/− standard error. b Confocal microscopy visual izing act ive caspase 1 in per itoneal
macrophages i) l eft untreated or ii) treated with LLOME (0.5 mM) for 0.5 h or iii) 2 h. Cell s wer e incubat ed with the affinity-based FLICA probe,
FAM-FLICA-FMK for 1 h, pr ior to washing and fixat ion. Images repr esentat ive of 3 independent exper iment s, scal e bar = 40 μm. c ELISA analysis of
IL-1β released over t ime from LPS-pr imed BMDMs following treatment with LLOME (0.5 mM) for 0.5 h to 6 h, n = 4 +/standard error. d Confocal
microscopy visual izing act ive caspase 1 in macrophages i) l eft untreated or treated for 2 h with ii) 500 μg/mL alum, iii)250 μg/mL sil ica , iv) 500 μg/mL
PSNP. e Confocal microscopy visual izing act ive caspase 1 in macrophages i) treated with LLOME (0.5 mM) for 2 h or ii) pr e-treated with bafilomycin
(250 nM) or iii) E64d (50 μM) pr ior to treatment with LLOME (0.5 mM) for 2 h. f ELISA analysis of IL-1β r el ease from LPSpr imed per itoneal
macrophages pr e-treated with bafilomycin (250 nM) or E64d (50 μM) pr ior to treatment with LLOME (0.5 mM) for 6 h, n = 3 +/− standard error
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become irreversibly attached to the active site of func-
tional proteases, such as caspases and cysteine cathepsins,
through nucleophilic attack of their highly active site thiol
group, therefore allowing target proteases to be labelled
[21, 22]. Accordingly, the application of a caspase 1-
selective fluorescent probe, FAM-Tyr-Val-Ala-Asp-FMK,
to detect and visualize the protease in macrophage
cultures was evaluated. Control cells not treated with
LLOME elicited no green fluorescent staining (Fig. 2b),
however, upon treatment of the cells with LLOME, a clear
cytoplasmic signal was observed from 0.5 h, which further
increased at 2 h post-treatment, indicative of caspase 1
activity (Fig. 2b). Both readouts of increasing caspase acti-
vation over time, following LLOME treatment, were con-
sistent with increased IL-1β secretion at the equivalent
concentration and at comparable time points, confirming
the utility of caspase 1 activity as a biomarker of lysosomal
rupture (Fig. 2c). Finally, using the caspase 1-selective
probe, caspase 1 activity was visualised in peritoneal mac-
rophages which had been treated for 2 h with alum, silica
and PSNP. Compared to the untreated cells, a clear
increase in cytoplasmic labelling of active caspase 1
was visible in the particle-treated cells, as seen by in-
creased green fluorescence (Fig. 2d). Taken together,
these results validate the approach of measuring and
visualizing intracellular caspase 1 activity as a surro-
gate biomarker for particle-induced lysosomal disrup-
tion and IL-1β release.
Inhibition of lysosomal acidification or inhibition of
cysteine cathepsins blocks caspase 1 mediated IL-1β
release
During the course of the experiments to detect caspase 1
activity, we also examined the role of lysosomal proteases
in the modulation of caspase 1 activity. Prior to treatment
with LLOME, we incubated cells with the H(+)-ATPase
proton pump inhibitor, bafilomycin A1, to abolish lyso-
somal acidification and thus cathepsin maturation and acti-
vation, showing that this reduced activation of caspase 1
(Fig. 2e). Similar depletion of caspase 1 activity was ob-
served through pre-incubation of cells with the cell perme-
able, pan cysteine cathepsin inhibitor, E64d (Fig. 2e(iii)). In
agreement with these effects on caspase 1 activity, it was
also found that inhibition of the lysosomal proteases led to
a significant decrease in the release of IL-1β, clearly
highlighting the role of cysteine cathepsin activity in the
control of caspase 1 activity (Fig. 2f).
Particle-induced lysosomal disruption induces release of
CTSS, which can be detected extracellularly
A predominant cathepsin found in macrophages and up-
regulated by pro-inflammatory stimuli is CTSS. We there-
fore asked what specific effect lysosomal disruption would
have on its activity levels. As with caspases, cysteine
cathepsins are also produced as inactive precursor zymo-
gens and therefore real-time assessment of activity is more
useful than analysis of protein levels alone. However, CTSS
has broader substrate selectivity than caspase 1; thus in
order to determine its activity levels accurately, selective
conditions and substrates are required. The tripeptide sub-
strate Z-Val-Val-Arg-AMC assayed at neutral pH can dis-
criminate CTSS over closely related cathepsins that have
inferior stability at neutralized conditions [23]. Using this
substrate, we first examined intracellular CTSS-like activity
levels in LPS-primed BMDMs, observing a higher specific
activity in wild type lysates when compared to ctss−/− ly-
sates, highlighting the stringency of the assay conditions in
specifically measuring CTSS activity (Fig. 3a). Interestingly,
following treatment of the cells with LLOME for a 2 h time
point, the levels of CTSS-like activity were reduced in
these lysates. As CTSS can remain active at cytosolic pH,
the observed time-dependent inactivation of this protease
by LLOME treatment may reflect the gradual inhibition of
CTSS by endogenous inhibitors, such as cystatins, or po-
tentially the secretion of this protease from the cell. As the
prognostic and diagnostic value of CTSS in serum levels
has previously been demonstrated for pathologies such as
diabetes, atherosclerosis and aortic aneurysm [24–26], we
also examined CTSS secretion from these cells by measur-
ing activities in the corresponding supernatants. Here it
was found that levels of CTSS activity rapidly increased at
0.5 h, following incubation of the cells with LLOME
(Fig. 3b). Furthermore, supernatants from cells treated with
LLOME for a longer 16 h time point demonstrated that
CTSS activity persists extracellularly highlighting its poten-
tial as a biomarker (Fig. 3c).
ABPs have also been developed for detection of active
CTSS. Incubation of the macrophage culture superna-
tants with the ABP, Biotin-PEG-Leu-Val-Arg-diazoke-
tone, permitted chemiluminescent detection of active
CTSS species via streptavidin-HRP conjugation to the
bound biotin reporter group. In agreement with the re-
sults using the fluorescently labeled substrate, detection
of active extracellular CTSS was only observed in the
LLOME-treated cells and was detectable at both 6 and
16 h post-treatment; with no CTSS labeling observed in
LLOME-treated ctss−/− supernatants (Fig. 3d). Next, we
confirmed that treatment of macrophages with particu-
late matter had the same effect on CTSS secretion.
Treatment of BMDMs with alum, silica or PSNP for 4 h,
resulted in an increase in CTSS activity in cell superna-
tants, as measured by increased turnover of the reporter
substrate Z-Val-Val-Arg-AMC (Fig. 3e). Taken together,
these results clearly demonstrate that extracellular CTSS
activity levels may also represent a useful biomarker of
lysosomal disruption and particle-induced inflammation
in macrophages and is detectable through use of sub-
strate and ABP technologies.
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IL-1β release is reduced in LLOME and particle treated
ctss−/− macrophages
Next, the functional significance of CTSS on IL-1β re-
lease in particulate-treated macrophages was assessed.
Using both wild type and ctss−/− peritoneal and BMDMs,
it was shown that LLOME treatment produced signifi-
cantly reduced levels of IL-1β in CTSS deficient cells
(Fig. 4a). In a time-course experiment in BMDMs
treated with 0.5 mM LLOME, we observed that the re-
duction in IL-1β release in the ctss−/− cells was able to
partially recover over time, with differences seen to a
greater extent at earlier time-points (Fig. 4a(iii)). This
implies that the role CTSS plays in IL-1β maturation is
an early onset effect and that at later time-points other
factors may be able to compensate. Finally, we then in-
cubated wild type and ctss−/− macrophages with alum,
silica or polystyrene particulates and again observed sig-
nificantly diminished IL-1β release in cells lacking CTSS,
in both peritoneal and BMDMs (Fig. 4b and c). Taken
together, these results indicate that CTSS plays a key
A) B)
C) D)
E)
Fig. 3 LLOME and particle-induced lysosomal rupture causes the release of active CTSS from macrophages. a CTSS activity in lysates measured as
increased RFU, produced from the proteolytic cleavage of the reporter substrate, Z-VVR-AMC (50 μM). Lysates were generated from BMDMs which
were left untreated or treated with LLOME (0.5 mM) for the indicated times. Ctss−/− cells were used as a control to determine background levels
of substrate turnover not due to CTSS, n = 3 +/− standard error. b Extracellular turnover of Z-VVR-AMC (50 μM) by CTSS in supernatants harvested
from BMDMs treated with LLOME (0.5 mM) for 0.5-2 h, n= 4 +/− standard error. c Extracellular turnover of Z-VVR-AMC (50 μM) by CTSS in supernatants
harvested from BMDMs treated with LLOME (0. 5 mM) for 16 h, n= 3 +/− standard error. d Cell supernatants were incubated with biotin-PEG-LVG-DMK
(10 uM) to label secreted mature CTSS from BMDMs treated with LLOME (0.5 mM) for 6 and 16 h. Supernatants from ctss−/− cells which had also been
treated with LLOME (0.5 mM) for 16 h were used as a control to confirm the identity of labeled CTSS. Blot is representative of 3 independent experiments.
e Extracellular turnover of Z-VVR-AMC (50 μM) by CTSS in supernatants harvested from BMDMs treated for 4 h with alum (500 μg/mL), silica (250 μg/mL)
or PSNPs (500 μg/mL), n= 3 +/− standard error
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role in the release of IL-1β in macrophages upon
particle-induced lysosomal disruption.
Both production of pro-IL-1β and Caspase 1 activity is
partially dependent on CTSS
Although we had established a role for CTSS in the release
of IL-1β, the absence of CTSS did not have a complete in-
hibitory effect on the release of this cytokine. Therefore,
the effect of CTSS knockdown in combination with cas-
pase inhibition was examined. Here we found that in the
ctss−/− macrophages, caspase inhibition still reduced IL-1β
levels in both peritoneal macrophages and BMDMs (Fig. 5a
and b). Next we compared intracellular caspase 1 activity
in peritoneal wild-type and ctss−/− macrophages using the
reporter substrate, Z-Tyr-Val-Ala-Asp-AMC, and the cas-
pase 1 ABP used previously. At 2 h post LLOME
treatment, marked caspase 1 activity was observed in both
wildtype and ctss−/− cells, as seen by increased substrate
turnover (Fig. 5c) and increased cytoplasmic green fluores-
cence from the ABP (Fig. 5d). However, consistent with re-
lease of IL-1β, there appeared to be reduced caspase 1
activity in the ctss−/− cells compared to wildtype cells.
Taken together, this suggests that under these conditions
in both peritoneal macrophages and BMDMs, the matur-
ation of IL-1β is caspase 1 dependent, as expected, but that
caspase 1 activity is modulated significantly by CTSS, con-
sistent with its release during lysosomal disruption.
It has been shown that components of the inflamma-
some, pro-caspase 1 and pro-IL-1β can be secreted from
macrophages upon treatment with cytoplasmic RNA, ATP
or nigericin [27, 28]. Therefore, having observed that CTSS
may contribute to the activation of caspase 1 following
A) i) ii) iii)
B) i) ii) iii)
C) i) ii) iii)
Fig. 4 IL-1β release is reduced in LLOME and particle treated ctss−/− macrophages. a ELISA analysis of secreted IL-1β levels in supernatants from
wildtype and ctss−/− i) LPS-primed peritoneal macrophages and ii) LPS-primed BMDMs which were treated for 16 h with LLOME (0.5 mM), n= 4 +/−
standard error. iii) ELISA analysis of secreted IL-1β levels in supernatants from wildtype and ctss−/− BMDMs which were primed with LPS (100 ng/mL) prior
to stimulation with LLOME (0.5 mM). Supernatants were harvested at timed intervals from 0.5 h to 4 h, n= 3 +/− standard error. b ELISA analysis of
secreted IL-1β levels in supernatants from wildtype and ctss−/− LPS-primed peritoneal macrophages which were treated for 16 h with a concentration
range of i) alum, ii) silica, iii) PSNP, n= 4 +/− standard error. c ELISA analysis of secreted IL-1β levels in supernatants from wildtype and ctss−/− LPS-primed
BMDMs which were treated for 16 h with a concentration range of i) alum, ii) silica, iii) PSNP, n= 4 +/− standard error
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lysosomal rupture, we wanted to establish if the effect of
CTSS on caspase 1-dependent IL-1βmaturation was occur-
ring inside or outside the cell. Western blot analysis of
lysates from BMDMs revealed that LLOME causes the ap-
pearance of mature IL-1β; which was markedly abrogated
in ctss−/− cells (Fig. 5e). This suggests that the role of CTSS
A)
D)
E)
i) ii) iii) iv)
B) C)
Fig. 5 IL-1β processing in macrophages is partially dependent on CTSS. ELISA analysis of IL-1β release in supernatants from: a Wildtype and ctss−/−
LPS-primed peritoneal macrophages and (b) Wildtype and ctss−/− LPS-primed BMDMs, which were pre-treated with Z-VAD-FMK (5uM) for 1 h prior to
stimulation with LLOME (0.5 mM) for 16 h, n = 3 +/− standard error. c Caspase 1 activity measured in lysates generated from wildtype and ctss
−/− BMDMs, untreated or treated with LLOME (0.5 mM) for 2 h. Activity was measured by RFU generated from caspase 1 mediated hydrolysis
of Z-YVAD-AMC (50 μM). Data presented as increased RFU in lysates from treated cells relative to untreated control, n = 5 +/− error. d Confocal
microscopy of active caspase in wildtype (WT) and ctss−/− peritoneal macrophages, treated for 2 h with LLOME (0.5 mM). Cells were incubated
for 1 h with FAM-YVAD-FMK prior to washing, fixing and nuclear staining. Top panel: FLICA probe (green) + dapi (blue). Bottom panel: FLICA probe only
(green). Images representative of 3 independent experiments, scale bar = 40 μM. e Western blot of the pro-form and active form of IL-1β in lysates
generated from wildtype and ctss−/− LPS-primed BMDMs treated with LLOME (0.5 mM) for 5 h, before being harvested, lysed and blotted for IL-1β
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in caspase 1-dependent processing of IL-1β is intracellular
under these assay conditions. Furthermore, no extracellular
caspase activity was detected using the fluorogenic sub-
strate Z-Tyr-Val-Ala-Asp-AMC (Additional file 1: Figure
S2). This further implies that the action of CTSS on caspase
1-dependent IL-1β maturation is intracellular and also con-
firms that the secretion of CTSS is specific and not merely
due to cell membrane permeabilisation occurring during
pyroptosis [29].
Discussion
Concerns regarding the potential of nanotherapeutics to
induce unwanted inflammatory and toxic side effects in
vivo are supported by studies which have shown that
particulates, such as alum, silica and monosodium urate,
can activate NLRP3 signaling and IL-1β release [8, 13,
15]. Notably, overproduction of IL-1β has been linked
causatively to silicosis [30, 31] and reduction of silicosis
in vivo has been observed upon treatment with an IL-1
receptor antagonist, as well as in IL-1β knockout mice;
suggesting that IL-1β is a key mediator of particle-induced
inflammation [32]. While IL-1β levels can be easily quan-
tified, with the rapidly growing field of proteolytic imaging
permitting real time, non-invasive in vivo imaging of in-
tact animal models or ex vivo imaging of patient samples,
proteolytic enzymes may prove more attractive prognostic
and diagnostic biomarkers. The identification of such bio-
markers may be of value during both preclinical and clin-
ical stages of the development of nanotherapeutics and
also in understanding the molecular basis of adjunvanti-
city and particle-induced inflammation.
In this study we have demonstrated that, upon lysosomal
rupture, a detectable increase in intracellular caspase 1 ac-
tivity can be measured using peptidyl substrates and ABPs,
which is in positive correlation with pro-inflammatory IL-
1β release. Furthermore, we have shown that active CTSS
is also released extracellularly upon lysosomal rupture.
This data validates the utility of using protease activity sig-
natures as rapid readouts of particle-induced lysosomal
disruption in macrophage populations. Moreover, we have
also identified CTSS as a critical factor in LPS-primed
macrophages during production and processing IL-1β, in-
duced by both LLOME and particulates.
Initially, the potential of particulates, composed of differ-
ent materials, to activate IL-1β responses in LPS-primed
murine macrophages was evaluated. While particles com-
posed of the biodegradable polymer, PLGA, had no effect
under these conditions, other non-biodegradable particles
perturbed lysosomal integrity and generated IL-1β in a
dose-dependent fashion, suggesting that these particulates
were acting similarly in these experiments. Subsequently,
we have demonstrated that direct lysosomal disruption
with LLOME was able to mimic the IL-1β release profile
induced by particulates, consistent with reports that
accumulation of insoluble particulates can cause lysosomal
disruption [13–15]. Using this model system, the potential
roles of upstream mediators were further explored in order
to identify biomarkers of particle-induced inflammation
that could be applicable for in vivo imaging.
As IL-1β maturation has been shown to be dependent
on both caspase 1 and lysosomal cathepsins, we sought
to utilize the activities of these enzymes as readouts of
toxicity. Firstly, using a fluorescently labelled affinity-
based probe, FAM-YVAD-FMK, levels of intracellular
caspase 1 were directly visualised in macrophages by
fluorescent microscopy. Upon treatment with LLOME,
caspase 1 activation was detected as early as 0.5 h and
increased at 2 hours. Activity levels correlated with IL-
1β release, demonstrating this protease could be used as
a real-time biomarker of lysosomal rupture.
Next, we examined the potential to use lysosomal ca-
thepsins in a similar capacity as signatures of lysosomal
disruption, focusing on CTSS. CTSS is a lysosomal cyst-
eine protease which is highly expressed in macrophages
[33], has specific roles in MHC class II antigen presenta-
tion [34], toll-like receptor signaling [35] and is impli-
cated in the pathology of multiple immune disorders,
including rheumatoid arthritis, emphysema and athero-
sclerosis [36–39]. Notably, CTSS can retain activity at a
neutral pH, outside the lysosomal pathway and also has
limited tissue expression compared to other ubiquitously
expressed cathepsins, meaning it could potentially give a
more specific signal, with less background if imaged
using ABP technology. [23, 33].
We demonstrate herein that the selection of an appro-
priate coumarin-linked peptidyl substrate coupled with
appropriate assay conditions to favour the more stable
CTSS over other members of the cysteine cathepsins, we
were able to accurately detect and measure CTSS activ-
ity. Using these assay conditions it was observed that
lysosomal destabilization with LLOME resulted in a
decrease of CTSS activity in total lysates at 2 h. A simi-
lar finding has been reported previously with respect to
a decrease in lysosomal cathepsin B activity upon treat-
ment of macrophages with silica [13], which may be a
consequence of the active protease species being quenched
by cystatin inhibitors, naturally found in the cytoplasm
[40]. Crucially, however, was the unanticipated effect that
lysosomal disruption had on secretion of CTSS, where an
increase in secreted CTSS activity was observed, using both
substrate and ABP approaches, following LLOME-induced
lysosomal rupture. Whilst extracellular expression of ca-
thepsins has been well documented, particularly in inflam-
matory and neoplastic conditions [16], it was surprising to
observe increased extracellular CTSS activity induced by
lysosomal disruption. While cathepsin B may also be se-
creted, this protease requires the reducing, slightly acidic
conditions of the lysosomes to facilitate activity, unlike
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CTSS. The molecular mechanisms underpinning cathepsin
secretion are poorly understood, nonetheless these results
reveal its utility as a potential extracellular biomarker of
lysosomal disruption.
These investigations also permitted investigation of
the possible relationship between CTSS and caspase 1
following lysosomal rupture. Cathepsins B, C and D have
been previously implicated at various stages of IL-1β re-
lease from macrophages, dendritic cells and microglial
cells, following treatment with a range of inflammatory
stimuli [13, 41–43]. In keeping with these previous ob-
servations, inhibition of lysosomal acidification and use
of a broad spectrum cysteine cathepsin inhibitor attenu-
ated IL-1β release. However, using ctss−/− macrophages
we identified CTSS as a major contributing factor for
IL-1β release in these studies.
Caspase 1 activation in the ctss−/− background was
subsequently examined, observing diminished activation,
consistent with CTSS modulating IL-1β release through
caspase 1.While we have shown that intracellular CTSS
levels decrease following lysosomal rupture, there is
likely to be a window of activation before CTSS becomes
inhibited by cystatins or exported from the cell. This is
supported by our observation that caspase 1 is active at
0.5 h post-LLOME treatment and lysates generated from
LLOME-treated cells at this time retained CTSS activity,
compared to a 2 hour time-point. However, it is note-
worthy that the reduction in caspase activity in stimu-
lated ctss−/− macrophages is only a partial effect, with
approximately 25 % less caspase 1 activity than stimu-
lated wildtype macrophages, suggesting CTSS may have
other roles in the IL-1β response, besides contributing
to caspase-1 activation.
In keeping with our reported findings, several studies
have demonstrated that for caspase 1-mediated process-
ing and secretion of mature IL-1β, particle-induced lyso-
somal rupture and subsequent cathepsin activity are
required [11, 13, 44]. It has also recently been reported
that following stimulation with alum, CTSS is crucial for
IL-1β release from dendritic cells both in vitro and in
vivo at the site of alum injection [45].
Interestingly, this was shown to be an inflammasome-
independent process, potentially implying an alternative
role for CTSS in the unconventional secretion of IL-1β.
Therefore, we suggest a hypothetical model whereby
CTSS may regulate multiple steps in the IL-1β response,
potentially playing a direct role in modulating caspase 1-
mediated processing of pro-IL-1β and also in unconven-
tional protein release pathways. It may also be possible
that the cytoplasmic presence of CTSS may be sensed as
a pro-inflammatory danger signal and clearly further
work is needed to dissect these speculative mechanisms.
Our findings that residual IL-1β was still detected in
the ctss−/− cells following lysosomal rupture, confirmed
the potential redundancy of cathepsins in the IL-1β re-
sponse. Time course studies implied that CTSS has an
early onset role IL-1β maturation, as at later time-points
the reduction of IL-1β in ctss−/− cells becomes less sig-
nificant, perhaps due to the eventual up-regulation of
other cathepsins as a compensatory effect. Importantly,
the broad spectrum inactivation of lysosomal cathepsins,
with E64d and bafilomycin, attenuated release of IL-1β
and caspase 1 activity to a greater extent than that seen
in the ctss−/− macrophages, indicating the involvement
of other proteases, such as cathepsin B, which is sup-
ported by a recent study exploring the redundancy of
various cathepsins in inflammasome activation and the
IL-1β response [44].
Conclusion
Taken together, we have demonstrated that extracellular
CTSS activity levels and intracellular caspase 1 activity
levels can act as surrogate biomarkers for lysosomal
disruption and particle-induced inflammation in vitro.
Furthermore, given recent reports that CTSS can be de-
tected in serum and bronchoalveolar lavage fluid, CTSS
may prove to be a meaningful clinical biomarker of
particle-induced inflammation. There are already excel-
lent reagents for the determination of caspase 1 activity
and although historically it has been challenging to de-
velop selective reagents towards CTSS, many recent
studies have highlighted new generation ABPs and sub-
strates that may overcome such bottlenecks [46, 47], and
indeed already applied to assess CTSS activity levels in
the serum of rheumatoid arthritis and osteoarthritis pa-
tients to stratify disease states [48]. In the future, the
pre-clinical and clinical application of such techniques
in assessing the real time activities of caspase 1 and
CTSS could prove extremely useful in determining acute
particulate-induced inflammation during the develop-
ment of nanotherapeutics.
Methods
Cell isolation and culture
Primary cells used in the following experiments were ex-
tracted from aged-matched C57BL/6 mice and CTSS de-
ficient mice (ctss−/−) subsequent to euthanasia by CO2.
C57BL/6 mice were purchased from Charles Rivers
Laboratories and ctss−/− mice were obtained from J. A.
Joyce, Memorial Sloan Kettering Cancer Center, New
York. Animal handling, housing and primary cell isolation
was carried out in accordance with the UK Home Office
and approved by Queen's University Belfast Ethical Review
Committee.
Peritoneal macrophages were isolated through injec-
tion of sterile PBS into the peritoneal cavity. Cells
were washed is PBS, counted, seeded and left to ad-
here for at least 2 hours prior to treatments. Cells
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were then cultured in DMEM medium which was sup-
plemented with 10 % low endotoxin fetal calf serum
and 1 % penicillin/streptomycin, in a 37 °C, 5 % CO2
humidified incubator. Bone marrow derived macro-
phages were generated from flushing the leg bones of
C57BL/6 mice and ctss−/− mice to isolate bone marrow.
Bone marrow cells were then cultured for 1 week in
DMEM supplemented with 30 % L929 supernatant,
containing granulocyte-macrophage colony-stimulating
factor (GM-CSF), to drive differentiation.
To induce expression of pro- IL-1β, all cells were
primed for 3 h with toll-like receptor ligand Escherichia
coli R515 LPS (100 ng/mL) (InvivoGen) prior to treat-
ments with particulates or LLOME (Sigma). PSNP and
silica nanoparticles were 100 nm in diameter and posi-
tively charged and were purchased from Micromod in
25 mg/mL suspensions. Alhydrogel adjuvant, referred to
as ‘alum’ throughout this manuscript, was purchased
from Invivogen in a 10 mg/mL suspension and particles
were an average of 10 μm in diameter and of neutral
charge. Blank PLGA nanoparticles, 150 nm in diameter
and of neutral zeta potential were prepared as described
in [49]. Cells were treated for the time-points stated and
where indicated, cells were pre-incubated for 1 h with
50 μM E64d (Enzo Life Sciences), 250 nM bafilomycin
A1 (Sigma) or 5 μM Z-VAD-FMK (Calbiochem).
ELISA
Cell culture supernatants were assayed for IL-1β secre-
tion using an R&D DuoSet ELISA (DY401), according to
manufacturer’s instructions.
Confocal microscopy
Following treatments, living cells were incubated for 1 h
with caspase 1 probe, FAM-YVAD-FMK, according to
manufacturer’s instructions (Immunochemistry Tech-
nologies). Alternatively, cells were incubated for 0.5 h
with 2.5 μM acridine orange (Thermofischer Scientific)
to label acidic lysosomal compartments. After being
washed in PBS twice, cells were fixed in 4 % Paraformal-
dehyde in PBS for 20 mins, mounted with ProLong Gold
Antifade Mountant containing DAPI (Invitrogen) and
visualised using a Nikon TE EZ-C1 confocal system
(Nikon, Kingston Upon Thames). Images were captured
with a 60 × objective lens and a 1024 × 1024 for the cas-
pase 1 probe and a 512 × 512 frame for the lysosomal
staining.
Caspase 1 activity assay
Following treatments, BMDMs were lysed in Hepes lysis
buffer (25 mM Hepes, 100 mM NaCl, 2 nM EDTA,
0.1 % CHAPs, 10 % sucrose, pH 7.4) according to
Thornberry et al., [6]. Lysates (80 μg) were incubated
with fluorogenic substrate, Z-YVAD-AMC (50 μM)
(Enzo Life Sciences) to measure caspase 1 activity in ac-
tivity buffer (50 mM Hepes, 10 % sucrose, 1 % CHAPS.
1 mM EDTA, 10 mM DTT, 1 mM PMSF, 10 μM E64,
10 μM pepstatin A). Substrate turnover was measured
after 1 h at excitation/emission 385 nm/460 nm.
Cathepsin S activity assay
Following treatments, BMDMs were harvested and lysed
in sodium acetate lysis buffer (100 mM NaOAc, 100 mM
NaCl, 0.1 % Triton X-100, pH 5.5) by incubation on ice
for 0.5 h, followed by pulse sonication. Lysates were then
clarified by centrifugation at 14,000 x g for 10 mins at 4 °
C. Lysates were then incubated with sodium phosphate
buffer (0.1 M Na2HPO4, 0.1 M NA2H2PO4, pH 7.4) for 45
mins to inactivate other cathepsins. At this point lysate
mixtures or cell supernatants were added to MES reaction
buffer (0.5 M MES, 1 mM EDTA, 2 mM DTT, pH 6) and
50 μM Z-VVR-AMC (Enzo Life Sciences) was then added.
Substrate turnover was measured after 1 h at excitation/
emission 385 nm/460 nm.
Cathepsin S ABP labelling
Supernatants from BMDMs that had been treated with
LLOME for the indicated time-points were diluted in MES
reaction buffer and incubated at 37 °C for 15 mins with
10 μM biotin-PEG-LVG-DMK. The reaction was termi-
nated by addition of 5X Laemmli buffer and denaturation
at 95 °C. Samples were resolved by 15 % SDS-PAGE and
transferred onto nitrocellulose PVDF membranes (Milli-
pore), blots were subsequently blocked in 5 % BSA in TBS/
tween overnight at 4 °C. The membrane was then incu-
bated with Streptavidin-horse radish peroxidase (Cell Sig-
naling) diluted TBS/Tween, with 5 % BSA for 0.5 h at
room temperature. Proteins were imaged using ECL Plus
chemiluminescent substrate (ThermoFisher Scientific) and
exposed using the ChemiDoc XRS imaging system (BioRad
Laboratories).
Immunoblot analysis
Lysates generated from BMDMs, were separated by 15 %
SDS-PAGE and transferred onto nitrocellulose PVDF
membranes (Millipore). Blots were immersed in 5 % milk
powder in TBS/tween and incubated overnight at 4 °C
with a rat monoclonal antibody for IL-1β (RnD Systems
AF-501). Membranes were then washed and incubated
with rabbit anti-rat secondary antibody (Abcam). Proteins
were imaged using ECL Plus chemi luminescent substrate
(ThermoFisher Scientific) and exposed using the Chemi-
Doc XRS imaging system (BioRad Laboratories).
Statistical analysis
Data was analyzed for statistical significance using Graph-
Pad software. The experimental values are shown as the
means +/− standard error. An unpaired t-test was used
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for all analyses and a P-value of <0.05 was considered to
indicate statistical significance.
Additional file
Additional file 1: Figure S1. PLGA does not induce release of IL-1β in
peritoneal macrophages. ELISA analysis of IL-1β production in supernatants
peritoneal macrophages which were primed for 3h with LPS (100ng/ml)
and stimulated for 16h with a concentration range of PLGA. Figure S2.
LLOME does not induce extracellular caspase1 activity. Caspase 1 activity in
supernatants from LPS-primed BMDMs, treated with LLOME (0.5mM) for
45 mins to 6h. Activity was measured by RFU, generated from caspase
1 mediated hydrolysis of Z-YVAD-AMC. (PPTX 56 kb)
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